Feasibility of empirical chemotherapy before operation in children with
hepatoblastoma diagnosed by elevated serum alpha-fetoprotein
Abstract
Background To explore the feasibility of preoperative empirical
chemotherapy in the clinical practice of child hepatoblastoma from the
accuracy of clinical diagnosis based on elevated AFP and the effect of
preoperative empirical chemotherapy on treatment results. Procedures
Firstly, a retrospective analysis was made on clinical data of 80
children with primary hepatic space-occupying lesions admitted to a
single center in the past 5 years, including 50 cases of hepatoblastoma
and 30 cases of non-hepatoblastoma. Statistical way was used to analyze
the sensitivity and accuracy of differentiating child hepatoblastoma
from other liver space occupying lesions based on elevated serum
alpha-fetoprotein (AFP). Secondly, among the 50 children with
hepatoblastoma, those who had pathological evidence before chemotherapy
were classified as the pathological treatment group, and those who
started chemotherapy according to the clinical diagnosis of
hepatoblastoma based on the elevated AFP were assigned to the empirical
chemotherapy group. The survival of the two groups and distribution of
pathological types of the two groups were statistically analyzed.
Results According to the elevation of serum AFP, the liver primary
occupying lesions in children was clinically determined as
hepatoblastoma. The sensitivity and specificity were 98% and 100%.
There was no significant difference in overall survival (OS) and
event-free survival (EFS) between pathological treatment group and the
empirical chemotherapy group by the Log-rank test. Conclusion The
diagnosis of hepatoblastoma based on the elevated serum AFP can be used
to guide the preoperative empirical chemotherapy in children with poor
surgical tolerance and to minimize the risk of treatment.